Health
Pfizer's Talzenna Wins Phase 3 for Earlier Prostate Cancer Use
Pfizer's PARP inhibitor Talzenna succeeded in a Phase 3 prostate cancer trial when combined with Xtandi, setting up a regulatory push to expand the drug's use to earlier-stage patients.
DE
DT Editorial AI··via endpoints.news